Company Encyclopedia
View More
name
Neuronetics
STIM.US
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.
1.407 T
STIM.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking85/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-242.27%E
    • Profit Margin-34.27%E
    • Gross Margin45.87%B
  • Growth ScoreA
    • Revenue YoY78.62%A
    • Net Profit YoY-22.18%D
    • Total Assets YoY96.26%A
    • Net Assets YoY234.29%A
  • Cash ScoreC
    • Cash Flow Margin-291.84%D
    • OCF YoY78.62%A
  • Operating ScoreA
    • Turnover1.18A
  • Debt ScoreE
    • Gearing Ratio78.44%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference

    MALVERN, Pa., Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Neuronetics, Inc., ( NASDAQ: STIM ) ( the "Company" or "Neuronetics" ) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they ...

    GlobeNewswire·
    US
    STIM
    -4.83%
    GlobeNewswire·
    US
    STIM
    -4.83%

    TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression | STIM Stock News

    TRICARE West has expanded coverage for NeuroStar® TMS therapy to adolescents aged 15 and older, effective immediately across 26 states. This policy update aims to provide access to non-drug treatment for depression, addressing the mental health needs of military families. Neuronetics, Inc. emphasizes the importance of this decision, highlighting the significant impact of depression on adolescents. NeuroStar TMS therapy is now recognized by several insurers and is the first TMS treatment cleared by the FDA for adolescents. Neuronetics operates treatment centers nationwide, offering innovative mental health solutions.

    StockTitan·
    US
    STIM
    -4.83%
    StockTitan·
    US
    STIM
    -4.83%

    Neuronetics Reports Strong Q3 Growth and CEO Transition

    Neuronetics, Inc. reported strong Q3 growth with a 101% revenue increase to $37.3 million, driven by its Greenbrook clinic acquisition. Key highlights include a 25% growth in U.S. Greenbrook clinic revenue and a strengthened balance sheet with $34.5 million in cash. Despite a decrease in gross margin to 45.9%, the company improved cash management, using only $0.8 million in operations. Neuronetics secured $10 million in funding and expanded Medicaid coverage for its TMS therapy in New York. The company expects total revenue between $147 million and $150 million for 2025 and aims for positive cash flow by year-end.

    Tip Ranks·
    US
    STIM
    -4.83%
    Tip Ranks·
    US
    STIM
    -4.83%

    Neuronetics’ Earnings Call: Growth Amid Challenges

    Neuronetics reported a 101% increase in total revenue to $37.3 million for Q3 2025, driven by successful integration of Greenbrook operations. However, challenges persist with a 4% decline in NeuroStar revenue and a drop in gross margins to 45.9%. The company improved cash flow, reducing operational cash use to $0.8 million. Despite a net loss of $9.4 million, Neuronetics adjusted its full-year revenue guidance down to $147-$150 million. Looking ahead, Q4 revenue is projected between $40-$43 million, reflecting strategic adjustments for financial stability.

    Tip Ranks·
    US
    STIM
    -4.83%
    Tip Ranks·
    US
    STIM
    -4.83%

    Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan

    Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus ...

    GlobeNewswire·
    US
    STIM
    -4.83%
    GlobeNewswire·
    US
    STIM
    -4.83%
    © 2025 Longbridge｜Disclaimer